Esperion Therapeutics, Inc. (ESPR)

NASDAQ: ESPR · Real-Time Price · USD
3.120
-0.180 (-5.45%)
At close: Oct 6, 2025, 4:00 PM EDT
3.100
-0.020 (-0.64%)
After-hours: Oct 6, 2025, 6:27 PM EDT
-5.45%
Market Cap629.06M
Revenue (ttm)268.13M
Net Income (ttm)-104.02M
Shares Out 201.62M
EPS (ttm)-0.53
PE Ration/a
Forward PE32.50
Dividendn/a
Ex-Dividend Daten/a
Volume7,817,404
Open3.290
Previous Close3.300
Day's Range3.110 - 3.420
52-Week Range0.693 - 3.940
Beta0.96
AnalystsBuy
Price Target6.50 (+108.33%)
Earnings DateNov 6, 2025

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD... [Read more]

Sector Healthcare
IPO Date Jun 26, 2013
Employees 304
Stock Exchange NASDAQ
Ticker Symbol ESPR
Full Company Profile

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 108.33% from the latest price.

Price Target
$6.5
(108.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Re...

3 days ago - GlobeNewsWire

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL Third Largest Global Market for Cardiovascular Prevention Represents Significant...

17 days ago - GlobeNewsWire

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Cantor Global Healthcare Conference 2025 September 3, 2025 9:45 AM EDT Company Participants Benjamin Halladay - Chief Financial Officer Sheldon Koenig - Pres...

4 weeks ago - Seeking Alpha

Top 2 Health Care Stocks That May Plunge This Month

As of Sept. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: NUVB
4 weeks ago - Benzinga

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –

5 weeks ago - GlobeNewsWire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Espe...

2 months ago - GlobeNewsWire

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Off...

2 months ago - Seeking Alpha

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – ...

2 months ago - GlobeNewsWire

Esperion to Report Second Quarter 2025 Financial Results on August 5

ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.

2 months ago - GlobeNewsWire

Esperion Appoints Craig Thompson to Board of Directors

Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience

3 months ago - GlobeNewsWire

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Mana...

4 months ago - Seeking Alpha

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limite...

5 months ago - GlobeNewsWire

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Confer...

5 months ago - GlobeNewsWire

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Inno...

5 months ago - GlobeNewsWire

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Ch...

5 months ago - Seeking Alpha

Esperion to Participate in The Citizens Life Sciences Conference

ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, a...

5 months ago - GlobeNewsWire

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across...

5 months ago - GlobeNewsWire

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology ...

6 months ago - GlobeNewsWire

Esperion Appoints Robert E. Hoffman to Board of Directors

- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Rob...

6 months ago - GlobeNewsWire

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and ...

7 months ago - Seeking Alpha

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million –

7 months ago - GlobeNewsWire

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – – Esperion to Receive an Upfront Payment and Near-Term Milestones Along with...

7 months ago - GlobeNewsWire

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025.

8 months ago - GlobeNewsWire

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –

10 months ago - GlobeNewsWire

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational im...

Other symbols: CRDFUIVODDEFLNCGASSHII
10 months ago - Seeking Alpha